RE:RE:RE:CXR
("why aren't the 60 new ones accounted for")? are you suggesting that the sales performance and margin on the 60 drugs that aren't even launched yet are factored into the guidance? how would they predict that so early on?
the other point about debt is that, as Mark "tucks in" acquistions, he will delever without paying any debt down. he will attack the debt in multiple ways and thats why he is so confident that its "manageable". again, jmo